years)
. 11 In the present study, we investigated the effects of 2 LAs (ropivacaine and lidocaine) on the growth of HuH7 12 and HepaRG human HCC cells. HepaRG cell line exhibits a unique property to differentiate into well-differentiated hepatocytes from highly proliferative progenitor cells. 13 We have previously shown that HepaRG cells represent a suitable model in HCC carcinogenesis. 14, 15 We hypothesized that LAs would specifically inhibit the viability and proliferation of HCC cells.
METHODS

Cell Lines and Experimental Procedure
HuH7 and HepaRG cell lines were established and maintained as previously described. 12, 16 HuH7 cells were grown in Dulbecco's Modified Eagle's medium (with l-glutamine-d glucose without pyruvate sodium) supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin. HepaRG cells were grown in William's E medium supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin, 5 μg/mL insulin, and 50 μmol/L hydrocortisone hemisuccinate. Differentiation of HepaRG cells from proliferative progenitors to mature well-differentiated hepatocytes was achieved in 4 weeks by culturing the cells in the supplemented medium in the presence of 2% dimethyl sulfoxide for the last 2 weeks as previously described.
14 All cell cultures were conducted at 37°C in a 5% CO 2 atmosphere. Independent culture experiments were performed at least in triplicate. It was not feasible for the experimenters (G.L.G., H.B., and G.A.) to be blind to the experimental conditions. Cells were incubated with or without LAs for 24, 48, or 72 hours. Ropivacaine (7.5 mg/mL) (Kabi, Heudebouville, France) and lidocaine (10 mg/mL) (Aguettant, Lyon, France) were diluted with the corresponding cell culture medium depending on the cell line (see above) to achieve the tested concentrations (from 10 were assessed over 72 hours. Concentrations, number of cells, and number of experiments were chosen in accordance with previous published data. 7, 14 Cell Viability and Proliferation Cells were seeded into 96-well plates (20,000 cells per well for HuH7 and HepaRG progenitors and 50,000 cells per well for differentiated HepaRG cells). Viability was assessed at 24, 48, or 72 hours with a MTT colorimetric assay. 17 Cytotoxicity of ropivacaine and lidocaine on Huh7 and HepaRG progenitors was evaluated by measuring lactae deshydrogenase (LDH) activity (Pierce LDH cytotoxicity assay; Thermofisher). LDH assay determines the release of cytoplasmic enzyme lactate dehydrogenase due to plasma membrane damage. LDH assay results were expressed in percentage of cytotoxicity by subtracting the LDH activity of the spontaneous LDH release control (water treated) from the chemical-treated sample LDH activity, divided by the total LDH activity [(maximum LDH release control activity) − (spontaneous LDH release control activity)], and multiplied by 100, following manufacturer instructions. DNA synthesis was assessed using the Click-iT Plus Edu Assay (Molecular Probes). Edu assay results were expressed in percentage of marked cell, by dividing the number of stained cell by the number of nucleus assessed by Hoechst.
Cell Cycle Analysis
Cell cycle phases were analyzed using a Cellomics Arrayscan Vti (Thermoscientific Laboratory, Villebon-sur-Yvette, France). Cells were seeded into 96-well plates with or without LAs. After 48 hours, cells were fixed for 20 minutes at 4°C with an acetic alcohol solution. Fixative was removed and each well was washed with PBS. Cells were then incubated with a Hoechst solution for 20 minutes, washed, and dried. Images were captured using an Olympus microscope and Cellomics Arrayscan Vti, allowing cell quantification in different phases of the cell cycle. Experiments were performed on HuH7 and HepaRG progenitors cells treated with 10 −4 M lidocaine and ropivacaine.
Apoptosis Test
The activity of caspase-3/7 (CPP32/apopain)-like proteases was determined using the EnzChek Caspase-3 Assay Kit following manufacturer instructions. Briefly, 5 × 10 5 HepaRG cells on 6-well plates were incubated with or without LAs following the same procedures as the MTT assay. After 48 hours, the cells were washed with PBS, lysed, and caspase activity in the extracts was measured. Fluorescent product of the Z-DEVDrhodamine 110 substrate generated by caspase-3-like proteases was detected by a Polarstar Omega fluorometer with excitation/emission at 496/520 nm. Background fluorescence was determined by following the same procedures without cells and subtracted from the total. Negative control was performed by including a specific caspase-3 inhibitor (Ac-DEVD-CHO) in HepaRG cells. Positive control was performed by treating HepaRG cells with doxorubicin (50 ng/mL). 18 Apoptosis was also detected in situ by using a Click-iT Plus TUNEL assay (Molecular Probes, Villebon-sur-Yvette, France). Results were expressed in percentage of marked cell by dividing the number of stained cells by the number of nuclei assessed by Hoechst.
Senescence Test
Senescence-associated β-galactosidase activity was detected with a Cellular Senescence Assay Kits KAA002 (Merck Millipore, Saint Quentin-en-Yvelines, France). Cells were grown with LAs, washed in PBS, fixed for 3-5 minutes at room temperature in 2% formaldehyde/0.2% glutaraldehyde, washed, and incubated at 37°C (No. C02) with fresh senescence-associated (3-Gal [SA-, 3-Gal]) stain solution (1 mg of 5 bromo-4-chloro-3-indolyl P3-D-galactoside [X Gal] per mL/40 mM citric acid/sodium phosphate, pH 6.0/5 mM potassium ferrocyanide/5 mM potassium ferricyanide/150 mM NaCl/2 mM MgCl 2 ). Then stained cells were count under optical microscopy.
Microarray Analysis
Total RNA was purified from cells with miRNeasy Mini Kit (Qiagen, Courtaboeuf, France). Quantity and quality of RNA were evaluated with a Nanodrop ND-1000 spectrophotometer (Nyxor, Palaiseau, France). Genome-wide expression profiling was conducted using a 1-color, low-input Quick Amp Labelling Kit and human SurePrint G3 8x60K pangenomic microarrays (Agilent Technologies, Les Ulis, France), www.anesthesia-analgesia.org
ANESTHESIA & ANALGESIA
Local Anesthetics Inhibit HCC Cells as previously described. 19 Briefly, differentially expressed genes were identified by a 2-sample univariate t test with a random variance model. Individual genes were selected on the basis of both statistical significance (P < .01) and fold change (FC) difference between the compared groups (FC > 1.5). Microarray experiments were performed on HuH7 cells treated with 10 −3 M lidocaine and ropivacaine for 48 hours. Microarray data mining was performed as previously described using Gene Set Enrichment Analysis and Gene Ontology data mining tools. 19 
Real-Time Reverse Transcriptase Polymerase Chain Reaction
Relevant genes from microarray data were chosen to confirm the effects of LAs (10 −3 M and 10 −4 M) on HuH7 and HepaRG cells. Gene expression was measured by quantitative real-time polymerase chain reaction (QRT-PCR), as done previously.
14 Quantitative analysis of PCR data was conducted with the 2 −ΔΔCt method using β-actin Ct values for normalization. Melting analysis was conducted to validate the specificity of PCR products. 
Western Blot
Protein extraction was performed after 48 hours of LA treatment using a RIPA Lysis and Extraction Buffer (Life Technologies, Marly-le-Roi, France). Protein concentration was determined with a Pierce bovine serum albumine (BSA) Protein Assay kit (Thermo Scientific) by absorbance measurement at 562 nm. NuPAGE LDS Sample Buffer (4X) and NuPAGE Sample Reducing Agent (10X) (Life Technologies) were mixed with 30 μg of protein; H 2 O was added for a final volume of 15 μL. The mixture was incubated for 10 minutes at 70°C. After gel migration for 45 minutes at 200 V (NuPAGE Novex 4%-12% and 20X NuPAGE MOPS SDS Running Buffer, Life Technologies), proteins were transferred into a membrane using a Blot Dry Blotting System (Invitrogen, Paris, France). Nonspecific sites were saturated with an ECL Advance Blocking Agent (GE Healthcare, Velizy, France). Primary and secondary antibodies were diluted (1/10,000) in BSA 3% and tris buffered saline (TBS) 1%. Antibodies were incubated for at least 1 hour (APC Antibody [C-20], sc-896 Santa Cruz Biotechnology; antirabbit Antibody, DAKKO; Cyclin antibody sampler Kit #9869; Cell Signal Technology, Saint Quentin-en-Yvelines, France). The detection was performed with an ECL Advance Western Blotting Detection Kit (GE Healthcare). Quantification was achieved by densitometry analysis.
Statistical Analysis
Normal distribution of data was assessed with a ShapiroWilk test. The effects of the different concentrations of LAs on HCC viability were compared using a 2-way (cell type, LAs concentration) analysis of variance. In case of significant concentration or cell effect or of cell × concentration interaction (when comparing the effects of the different concentrations of LAs on HCC viability), pair-wise comparisons were performed using the Tukey test to control the overall rate of type I error due to multiple comparisons. Other comparisons between quantitative variables were performed using the Student t test or Wilcoxon rank sum test when needed. In these analyses, P < .05 after adjustment for multiple comparisons was considered statistically significant. Results are presented as percentages of variation between the mean of the group of interest versus control. In the microarray analysis, we identified genes that were differentially expressed among the 2 classes using a random-variance t test. The random-variance t test is an improvement over the standard separate t test as it permits sharing information among genes about within-class variation without assuming that all genes have the same variance. 20 The genes were considered to be differentially expressed between the 2 conditions (treated versus control) when P < .01 and a FC > 1.5. A more stringent statistical threshold was also applied for ropivacaine versus control: P < .001 and FC > 2. For experiment on cell viability (Figure 1 ), a sample size of at least 7 experiments per group allowed to have 97% power to detect at the 0.050 level a difference in means characterized by a variance of means of 0.042 (corresponding to expected values of 1.3 in HuH7 group, 1 in HeparRG, and 0.8 in HepaRG progenitors cells), assuming that the common standard deviation is 0.200. These differences corresponded to an expected benefit of at least 25% with ropivacaine and 60% with lidocaine as compared with placebo. With our results, 6 experiments per group for lidocaine and 8 per group for ropivacaine were sufficient to detect the observed difference with 90% power. For experiments on mRNAs levels of genes of interest (Figure 3 ), QRT-PCR (Figures 4 and 5) , and caspase activity, a sample size of at least 3 experiments per group allowed to have 90% power to detect an effect size of at least 3.6 for ropivacaine and lidocaine at the 0.050 level using a 2-group t test. The statistical analysis was performed using SAS statistical software V9.3 (SAS Institute, Cary, NC).
RESULTS
Lidocaine and Ropivacaine Reduce Cell Viability of Proliferative Tumor Cells
The effects of LAs on cell viability were first evaluated on HuH7 and HepaRG cell lines at 48 hours ( Figure 1 ). There was a significant cell × concentration interaction (P < .001). Pair-wise comparisons showed that as compared with control, lidocaine and ropivacaine (concentrations ranging from 5 × 10 −3 M to 10 −4 M) significantly decreased the growth of HuH7 cells as follows: by 87% (P < .001) and 92% (P < .001) at 5 × 10 −3 M, 35% (P = .02) and 67% (P < .001) at 10 −3 M, 37% (P = .02) and 40% (P = .02) at 10 −4 M, respectively. Lidocaine and ropivacaine also decreased the proliferation of highly proliferative HepaRG progenitors (at concentrations of Table 2B , http://links.lww.com/AA/ B970). After 24 hours, the effect was less pronounced: The only significant effect was observed at 10 −3 M of lidocaine and ropivacaine, which significantly decreased the growth of HuH7 cells by 13% (P < .001) and 14% (P < .001), respectively. When testing the effects of decreasing concentrations of LAs over time, lidocaine and ropivacaine significantly decreased the growth of HuH7 cells by 50% (P = .01) and 77% (P < .001) at 72 hours, respectively.
Lidocaine Inhibits the Growth of HCC Cells by Increasing the Caspase 3 Activity
The observed reduced cell viability induced by LAs on highly proliferative cells prompted us to determine whether LAs impact the cell cycle. Lidocaine had no significant effect on the cell cycle but was associated with an increase in the number of apoptotic bodies (Figure 2 ). Unsupervised genome-wide expression profiling showed in Huh7 cells that lidocaine treatments (10 −3 M) for 48 hours resulted in the deregulation of 194 genes (P < .01; FC > 1.5) (Supplemental Digital Content 4, Figure  2A , http://links.lww.com/AA/B971 and Supplemental Digital Content 3, Table 2 , http://links.lww.com/AA/B970). No drastic effect of lidocaine on mRNA levels of cell cycle regulators or cyclins was observed (Supplemental Digital Content 4, Figure 2 , http://links.lww.com/AA/B971 and Supplemental Digital Content 5, Table 3 , http://links.lww.com/AA/B972). However, lidocaine increased by 10 times the mRNA levels of adenomatous polyposis coli (APC) (FC > 1.5; P < .01), which acts as an antagonist of the Wnt/β-catenin pathway ( Figure   3 ). Lidocaine had no effect on the expression of apoptosisrelated genes and protein such as caspases and poly (adenosin diphosphate (ADP) ribose) polymerases but increased mRNA levels of Harakiri (HRK), encoding a proapoptotic protein (Figure 3 ). QRT-PCR confirmed microarray results for genes coding for CCNA2 (no significant effect), CCNB1 (no significant effect), APC (on HuH7: 1800% increase at 10 
Ropivacaine Inhibits the Growth of HCC Cells by Stopping the Cell Cycle in G2 Phase
Cell cycle analysis demonstrated that ropivacaine treatment resulted in a drastic enrichment of cells in the G2 Table 4 , http://links. lww.com/AA/B975). Interestingly, ropivacaine was associated with a decrease in the expression of key cell cycle regulator genes, especially involved in the G2-M transition phase, namely cyclin A2 (CCNA2) (63% decrease; P < .01), cyclin B1 (CCNB1) (64% decrease; P = .02). Ropivacaine also decreased the expression of MKI67 a nuclear marker of cell proliferation (61% decrease; P < .01) (Figure 3 ). Gene Set Enrichment Analysis confirmed the negative enrichment of cell cycle-associated gene signatures in HuH7 cells treated with ropivacaine (Supplemental Digital Content 9, Figure 5 , http://links.lww.com/AA/B976). QRT-PCR validated the microarray data for CCNA 2 (on HuH7: 81% decrease at 
DISCUSSION
To our knowledge, this study is the first report on the antitumor effect of LAs on HCC cells. LAs were previously shown to inhibit cell growth and induce cell death in lung, 7 colon, 21 and pancreatic cancer cells. 22 In healthy tissue, cell growth and cell cycle are tightly regulated. The loss of this regulation due to gene mutation (eg, inactivation of the tumor suppressor gene TP53), epigenetic or genomic deregulation, is a hallmark of cancer cells and results in their uncontrolled proliferation, associated with apoptosis resistance. In the present study, we show that ropivacaine may stop the G2 phase of the cell cycle in HCC cells. Only a few reports have investigated the effects of LAs on the cell cycle. In noncancer cells, Lucchinetti et al 23 showed that lidocaine and bupivacaine inhibit the cell cycle of mesenchymal stem cell at the G1/S phase transition. In colon and pancreatic cancer cell lines, Bundscherer et al 22 observed a significant antiproliferative effect with of high concentrations of ropivacaine and bupivacaine. Ropivacaine was shown to inhibit colon cancer cells' voltage-gated sodium channels (NaV1.5) and metastatic colon cancer cell invasion. 8 In our study, ropivacaine inhibited the proliferation of HCC cells by stopping the cell cycle in G2 phase. It decreased the mRNA abundance of key cell cycle regulators, especially involved in the G2-M transition phase, namely cyclin A2, cyclin B1, cyclin B2, and cyclindependent kinase 1. Ropivacaine also decreased the expression of MKI67, a nuclear marker of cell proliferation. Indeed, the CDK1-cyclin A complex allows the cell cycle to progress from the S (DNA replication) to the G2 (preparation for cell division) phase and the CDK1-cyclin B complex allows the progression from G2 to M (cell division) phase. Moreover, ropivacaine increased apoptosis in HepaRG progenitor cells without any effect on cellular senescence. In our study, the effects of ropivacaine were more pronounced on HuH7 and HepaRG progenitor cells than on differentiated HepaRG cells. These observations suggest an enhanced effect of LA on highly versus poorly proliferated cells.
In noncancer cells, lidocaine at a high concentration has been shown to stop cell cycle at the S phase and to inhibit fibroblast multiplication. 24 In breast cancer cells, a potential antitumor effect of lidocaine was reported, associated with a demethylation effect 25 and a sensitization effect to cisplatin cytotoxicity. 26 In vitro, lidocaine enhanced natural killer cell cytotoxicity against lymphoblast cells at 0.01 and 0.1 μM. 27 Recently, Chang et al 28 reported that lidocaine and bupivacaine are cytotoxic for thyroid cancer cells. These 2 LAs damaged the mitochondrial membrane potential, lead to cytochrome C release, activation of caspases 3 and 7, poly(ADP-ribose) polymerase cleavage, and induction of BCI-2 associated X. In our study, lidocaine increased by 10 times the mRNA levels of APC and of DKK1, which both act as antagonists of the Wnt/β-catenin pathway. The effect of lidocaine on DKK1 was more modest than on APC. The Wnt/β-catenin pathway is long known to be involved in carcinogenesis, especially in HCC. 29, 30 Therefore, lidocaine could be of interest in HCC, particularly those subtypes with an increase activity of the Wnt/β-catenin pathway. In our study, the effects and the underlying mechanisms of action of lidocaine and ropivacaine were different. Different effects of each LA have been previously reported on different cell lines including T-cells, 31 neuronal cells, 32 and mesenchymal stromal cells. 33 In lung cancer cells, ropivacaine and lidocaine inhibiting effects on Src were mediated through different pathways. 7 Indeed, LAs possess distinct chemical structures and properties. Jose et al 34 previously reported a cell-type-and molecule-type-specific effect. In their study, levobupivacaine triggered a more potent cancer-specific reduction of viability than ropivacaine on certain cancer cell type. They hypothesized a different effect on mitochondrial respiratory chain and ATP synthesis. Moreover, the systemic anti-inflammatory effects of bupivacaine are not mediated through sodium channel inhibition 35 indicating that LAs exert their properties by acting on a variety of targets. The differences observed in previous studies as well as in the present study regarding ropivacaine and lidocaine remain mostly unexplained on a mechanistic level and need further experiments.
The effects of LAs on cell viability, cell cycle, genes, and pathways deregulation are dose dependent. 7 We observed the cytostatic effects of LAs on HCC cells for concentration ranging from 10 -2 to 10 -5 M. In vitro concentrations vary 36 used mammary epithelial cells as controls and reported toxicity with higher concentrations when compared with breast cancer cells. However concentrations were high in this study.
Many mechanisms by which LAs and regional anesthesia could exert an antitumor effect have been suggested in the literature: (1) a decrease in opioid requirement is always associated with the use of LAs and opioid might promote cancer cells proliferation 38 ; (2) regional anesthesia inhibits axonal transport 39 and therefore could stop the dissemination of cancer cells during surgery; (3) a direct inhibition of cancer cells growth by LAs. 7 Clinical studies on the potential benefit of LAs during cancer surgery have been published for more than 10 years. Although retrospective and with some methodological bias, these studies lead to the hypothesis that LAs could mitigate perioperative tumor growth and metastasis formation, 2,4,5 specifically in the setting of breast and prostate cancer. These clinical studies are echoing the experimental studies that have already reported a reduction of tumor cell growth by LAs in the specific settings of thyroid, 28 breast, 25 lung, 7 and colon 8 cancer for example. Moreover, Lucchinetti et al 23 showed how LAs impaired the proliferation of mesenchymal stem cell, which are known to play an important role in tumor progression. 40 This effect was associated with a potential detrimental effect on wound healing when LAs are administered directly on the wound. Our work is the first to report a mechanism of the inhibiting effect of 2 LAs on HCC cells. In addition to potential effects in the tumor microenvironment, our results showed that LAs may induce profound modifications in gene expression profiles of tumor cells, notably by modulating cell cycle-related genes resulting in a cytostatic effect and induction of apoptosis. Multiple pathways are involved in the modulation of cell growth. These pathways cross talk to modulate the balance between proliferation and apoptosis. Based on the literature, it is difficult to determine if there is a waterfall effect induced by LAs on these pathways. 23 However, the antiproliferative effect of LAs on HCC cells has to be balanced with the possible risks of LAs toxicity and wound healing impairment. Moreover, our results would transpose with difficulty in the clinical setting. Indeed, many elements such as the absence of stress and/or inflammation and/or opioids and/or pain could eventually interact with the effect of LAs. Both preclinical and clinical studies are required to further confirm the benefit of LAs on the outcome of HCC surgery. Due to its analgesic properties, intravenous lidocaine is already part of most anesthesia protocol for abdominal surgery. Studying its effect on preventing cancer recurrence would therefore be feasible in clinical practice. E
